In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delivering Cancer Diagnostics Tools

Executive Summary

Pharma is keenly interested in new cancer diagnostics tools, which in many cases are aimed at selecting the best therapy for a specific patient, measuring response to therapy and predicting or more sensitively measuring relapse. These technologies are often the same as those used in pharma's drug development efforts. But deciding with whom and how to ally for the development and distribution of tests is difficult, showing just how uncharted, and bumpy, is the current diagnostics terrain.
Advertisement

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Integrated Diagnostics and Personalized Care: An Interview With GE Healthcare
What New Cancer Pathway Programs Mean For The Drug Industry
With Genoptix, Novartis Continues Its Diagnostics Build-up
J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General
Taking Stock Of Qiagen
Quanterix Corp.
On-Q-ity Inc.
Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests
Her2 Testing: What's Old Is New

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel